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RUNX1
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Purpose: Aiming at regeneration of permanent cartilage like joint car-
tilage, this study screened natural and synthetic compound libraries to
discover a novel compound inducing chondrogenic differentiation without
hypertrophy. We further investigated the underlying molecular mecha-
nism.
Methods: As an efﬁcient monitoring system for chondrogenic differ-
entiation, we established stable lines of mouse chondrogenic ATDC5
cells expressing green ﬂuorescent protein under the control of type II
collagen promoter fused with four repeats of a Sox9 enhancer (COL2-
GFP). Chondrogenic differentiation was assessed by real-time RT-PCR
for COL2, aggrecan, chondromodulin-1 and COL10, toluidine blue and
Alcian blue stainings, and quantitative GAG assay in cultures of mouse
embryonic stem cells or immature mesenchymal C3H10T1/2 cells. The
downstream molecules were screened by a microarray analysis using
C3H10T1/2 cells. The COL2 promoter activity was determined using
HuH-7 cells transfected with a luciferase-reporter gene construct con-
taining the COL2 promoter above, and the speciﬁc binding to the iden-
tiﬁed region was veriﬁed by electrophoretic mobility shift assay (EMSA)
and chromatin immunoprecipitation (ChIP). For functional analyses, we
performed adenoviral overexpression of the gene or the small interfering
RNA in C3H10T1/2 cells, and compared the chondrogenic differentiation
as described above with respective empty-vector controls. Molecular in-
teractions were examined by immunoprecipitation, mammalian two-hybrid
system, and immunohistochemistry in the mouse growth plate. Finally,
cartilage formation in full-thickness defects of mouse knee cartilage was
histologically evaluated after transplantation of cell-sheets of mouse rib
chondrocytes with or without TM treatment.
Results: The COL2-GFP system showed that a small thienoindazole-
derivative compound T-198946 (TM) most strongly induced the GFP
ﬂuorescence as early as after 48 h of treatment. TM was conﬁrmed to
enhance chondrogenic differentiation but inhibit the further hypertrophic
differentiation in the cultures of precursor cells. The microarray screening
revealed that Runx1 was most strongly induced by TM among 581
up-regulated genes including Sox5 and Sox6. Deletion, mutagenesis,
and tandem-repeat analyses of the luciferase assay identiﬁed the core
responsive element of Runx1 in the COL2 promoter to be between
the −293 and −288 bp region containing a putative Runx-binding motif.
EMSA and ChIP assays conﬁrmed the speciﬁc binding of Runx1 to this
region. Although chondrogenic differentiation of C3H10T1/2 cells was little
enhanced by the Runx1 overexpression alone, it was much enhanced
by co-transfection with Sox5, 6, and 9 (the Sox trio), without inducing
the hypertrophy, as true of the effect of TM treatment. Gene-silencing
of Runx1, Sox5/6, or Sox9 suppressed the TM effect on chondrogenic
differentiation. In fact, Runx1 and the Sox trio were co-localized in the
proliferative and pre-hypertrophic chondrocytes of the mouse growth
plate, and their physical interaction was conﬁrmed by immunoprecipitation
and two-hybrid analysis. Finally, cell-sheets of TM-treated chondrocytes
ﬁlled the defects with cartilaginous tissue, while the control cell-sheets
did not.
Conclusions: A novel small compound TM promotes chondrogenic dif-
ferentiation without inducing hypertrophy, through production of Runx1
that cooperatively functions with the Sox trio. TM will herald a new era of
regenerative medicine of permanent cartilage, thus realizing an epochal
treatment of osteoarthritis.
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Purpose: The burden of osteoarthritis (OA) is best measured by its
impact on quality of life. Women are disproportionately affected by knee
OA. Our objective was to estimate the quality-adjusted life expectancy
losses for elderly women and men with symptomatic knee OA in the US.
Methods: We used NHANES III data to estimate the proportion of men
and women >60 years of age who had symptomatic knee OA. We applied
this distribution to the total population of persons >60 years of age
(obtained from 2000 US Census data) to estimate the actual number
of elderly persons with symptomatic knee OA in the US, stratiﬁed by
sex. Per person survival losses adjusted for quality of life were estimated
using the Osteoarthritis Policy Model (OAPol), a comprehensive computer
simulation model of natural history and clinical management of knee OA.
Model input parameters included data on the comorbidities and quality of
life decrements associated with symptomatic knee OA, obesity (BMI 30)
and other chronic diseases derived from NHANES III. OA progression
rates were estimated from the Johnston County Osteoarthritis Project
and calibrated using published literature. Background mortality rates (age,
sex, race-adjusted) were derived from US life tables.
Results: Approximately 10% (8.3 million) Americans (>60 y/o) have
symptomatic knee OA, 64% of whom are women. Women with symp-
tomatic knee OA will experience loss of approximately 6.3 million of
quality-adjusted years compared to 3.5 million quality-adjusted years of
life lost for men. Obesity, resulting in 65% of such losses, is a substantial
contributing factor (Figure) for both men and women.
Conclusions: There is a disproportionate burden of knee OA in women,
particularly in those women who are obese. These substantial losses in
quality-adjusted life expectancy underscore the importance of including
quality of life in assessment of public health and clinical interventions
focused on reducing the burden of knee OA. More research is needed
to understand the relative contributions of biology and environmental
exposures in explaining the differences observed between men and
women in OA-related disability.
